Planned interruptions of anti-HIV treatment

Lancet Infectious Diseases

Volumn 1, Issue 1, 2001, Pages 53-59

  Hirschel, Bernard ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LIPODYSTROPHY; METHODOLOGY; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; LIPODYSTROPHY;

EID: 0035436735     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00022-6     Document Type: Note

References (66)

1. Panel on clinical practices for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http://www.hivatis.org ; 2001.
2. Flepp M., Schiffer V., Weber R., Hirschel B. Modern anti-HIV therapy. Swiss Med Wkly. 131:2001;207-213.
3. Egger M., Hirschel B., Francioli P., et al. Impact of new anti-retroviral combination therapies in HIV-infected patients in Switzerland: prospective multicenter study. BMJ. 315:1997;1194-1195.
4. Henry K. The case for more cautious, patient-focused antiretroviral therapy. Ann Intern Med. 132:2000;306-311.
5. Carr A., Miller J., Law M., Cooper D.A. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 14:2000;F25-F32.
6. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
7. Kalams S.A., Goulder P.J., Shea A.K., et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viraemia with highly active antiretroviral therapy. J Virol. 73:1999;6721-6728.
8. Papasavvas E., Ortiz G.M., Gross R., et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 182:2000;766-775.
9. Izopet J., Massip P., Souyris C., et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS. 14:2000;2247-2255.
10. Verhofstede C., Wanzeele F.V., Van Der G.B., De Cabooter N., Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS. 13:1999;2541-2546.
11. Miller V., Sabin C., Hertogs K., et al. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 14:2000;2857-2867.
12. Ho D.D. Time to hit HIV, early and hard. N Engl J Med. 333:1995;450-451.
13. Vanhems P., Hughes J., Collier A.C., et al. Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney. AIDS. 14:2000;375-381.
14. Lyles R.H., Muñoz A., Yamashita T.E., et al. Natural history of human immunodeficiency virus type 1 viraemia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis. 181:2000;872-880.
15. Borrow P., Lewicki H., Wei X.P., et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 3:1997;205-211.
16. Evans D.T., O'Connor D.H., Jing P., et al. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med. 5:1999;1270-1276.
17. Jin X., Bauer D.E., Tuttleton S.E., et al. Dramatic rise in plasma viraemia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 189:1999;991-998.
18. Clerici M., Seminari E., Suter F., et al. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia. AIDS. 14:2000;109-116.
19. Mollet L., Li T.S., Samri A., et al. Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load. The RESTIM and COMET Study Groups. J Immunol. 165:2000;1692-1704.
20. Autran B., Carcelain G., Li T.S., et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
21. Autran B., Carcelain G. AIDS - boosting immunity to HIV - can the virus help? Science. 290:2000;946-947.
22. + T cell responses associated with control of viraemia. Science. 278:1997;1447-1450.
23. Davey R.T. Jr, Bhat N., Yoder C., et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. 96:1999;15109-15114.
24. Hatano H., Vogel S., Yoder C., et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS. 14:2000;1357-1363.
25. Lori F., Lewis M.G., Xu J., et al. Control of SIV rebound through structured treatment interruptions during early infection. Science. 290:2000;1591-1593.
26. Rosenberg E.S., Altfeld M., Poon S.H., et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 407:2000;523-526.
27. Chun T.W., Justement J.S., Moir S., et al. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies. Proc Natl Acad Sci USA. 98:2001;253-258.
28. Levy J.A. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 22:2001;312-316.
29. Klein M.R., van Baalen C.A., Holwerda A.M., et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med. 181:1995;1365-1372.
30. Pitcher C.J., Quittner C., Peterson D.M., et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 5:1999;518-525.
31. Ortiz G.M., Nixon D.F., Trkola A., et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 104:1999;R13-R18.
32. Markowitz M, Jin X, Ramratnam B, et al. Prolonged HAART initiated within 120 days of primary HIV-1 infection does not result in sustained control of HIV-1 after cessation of therapy. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 288).
33. Hermans P, Kabeya K, Wanzeele Van F, Verhofstede C, Clumeck N. Successful interruption of antiretroviral therapy (ARVT) in patients with primary HIV infection (PHI). 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 290).
34. Miró JM, Tortajada C, Plana M, et al. HIV-1-specific T-cell responses and spontaneous control of viraemia can be detected after the first cycle of structured treatment interruptions (STI) in patients receiving HAART since primary HIV-1 infection (PHI). 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 359).
35. Girard P.M., Schneider V., Dehee A., et al. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. AIDS. 15:2001;275-277.
36. Papasavvas E., Ortiz G.M., Gross R., et al. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 182:2000;766-775.
37. Haslett P.A., Nixon D.F., Shen Z., et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis. 181:2000;1264-1272.
38. Carcelain G., Tubiana R., Samri A., et al. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol. 75:2001;234-241.
39. Lisziewicz J., Rosenberg E., Lieberman J., et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 340:1999;1683-1684.
40. Lori F., Maserati R., Foli A., Seminari E., Timpone J., Lisziewicz J. Structured treatment interruptions to control HIV-1 infection. Lancet. 355:2000;287.
41. Fagard C, Lebraz M, Gunthard H, et al. SSITT: a prospective trial of strategic treatment interruptions in 128 patients. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 357).
42. Kilby J.M., Goepfert P.A., Miller A.P., et al. Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: a case report. Ann Intern Med. 133:2000;435-438.
43. Dybul M, Yoder C, Belson M, et al. A randomized controlled trial of intermittent versus continuous HAART. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 364).
44. Chun T.W., Engel D., Mizell S.B., et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med. 5:1999;651-655.
45. Phillips A, Youle M, Tyrer M, et al. CD4 count changes in people interrupting HAART therapy after a CD4 count increase. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 361).
46. Tebas P, Henry K, Mondy K, et al. CD4 decay after discontinuation of virologically successful antiretroviral therapy. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 355).
47. van Lunzen J, Frahm N, Schmitz, JE, et al., Treatment interruption (TI) leads to a rapid recurrence of immunological changes and viral load in chronic HIV-1 infection. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 363).
48. Dybul M, Chun TW, Yoder C, et al. Short-cycle intermittent HAART: a pilot study. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 354).
49. Hatano H., Miller K.D., Yoder C.P., et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS. 14:2000;1935-1942.
50. Carpenter C.C., Cooper D.A., Fischl M.A. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. JAMA. 283:2000;381-390.
51. Zuber B., Bottiger D., Benthin R., et al. An in vivo model for HIV resistance development. AIDS Res Hum Retroviruses. 17:2001;631-635.
52. Dorman K.S., Kaplan A.H., Lange K., Sinsheimer J.S. Mutation takes no vacation: can structured treatment interruptions increase the risk of drug-resistant HIV-1? J Acquir Immune Defic Syndr. 25:2000;398-402.
53. Bonhoeffer S., Rembiszewski M., Ortiz G.M., Nixon D.F. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS. 14:2000;2313-2322.
54. Neumann A.U., Tubiana R., Calvez V., et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS. 13:1999;677-683.
55. Ruiz L., Martinez-Picado J., Romeu J., et al. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS. 14:2000;397-403.
56. Deeks S.G., Wrin T., Liegler T., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viraemia. N Engl J Med. 344:2001;472-480.
57. Sabin A, Phillips A, Fusco J, et al. The effect of treatment interruption in patients with virologic failure: results from a multicohort collaborative study. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 365).
58. Papasavvas E, Kostman J, Ortiz GM, et al. Distinct outcomes to multiple treatment interruptions in chronic infection. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 362).
59. Plana M, Garcia F, Ortiz GM, et al. Influence of hydroxyurea (HU) associated with HAART and maintained during periods off antiretroviral therapy in STI on the HIV-1-specific immune responses. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 356).
60. +T cells response after three structured treatment interruptions (STI) of antiretroviral treatment (ART) in chronic HIV-infected patients. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 291).
61. Garcia F, Plana M, Ortiz GM, et al. Outcome after 1 Year of HAART, 3 cycles of STI and 12 months off therapy vs natural evolution without ART in early chronic HIV-1 infection (CHI). A case-control study. 8th Conference on Retroviruses and Opportunistic Infections; 2001; Chicago (abstr 289).
62. Spitler L.E., Grossbard M.L., Ernstoff M.S., et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 18:2000;1614-1621.
63. Cohen J. Merck reemerges with a bold AIDS vaccine effort. Science. 292:2001;24-25.
64. Barouch D.H., Santra S., Schmitz J.E., et al. Control of viraemia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290:2000;486-492.
65. Altman J.D., Lydy S.L., O'Neil S.P., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:2001;69-74.
66. Youle M., Janossy G., Turnbull W., et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine. AIDS. 14:2000;1717-1720.